#cancergrace

The Importance of Breast Cancer Screening
The Importance of Breast Cancer Screening
Treatment After Diagnosis of Breast Cancer
Treatment After Diagnosis of Breast Cancer
Symptoms of Breast Cancer
Symptoms of Breast Cancer
Anomalies on Breast Cancer Imaging: Next Steps
Anomalies on Breast Cancer Imaging: Next Steps
Types of Imaging Tests for Breast Cancer
Types of Imaging Tests for Breast Cancer
The Prevalence of Breast Cancer and Tools for Early Detection
The Prevalence of Breast Cancer and Tools for Early Detection
The Importance of Prostate Cancer Screening
The Importance of Prostate Cancer Screening
The Importance of Patient Centered Care
The Importance of Patient Centered Care
Goals of Lung Cancer Advocacy
Goals of Lung Cancer Advocacy
Key Players for Lung Cancer Program Success
Key Players for Lung Cancer Program Success
Treatment for Metastatic Melanoma
Treatment for Metastatic Melanoma
Mesothelioma Updates, Episode 6: Peritoneal Disease
Mesothelioma Updates, Episode 6: Peritoneal Disease
Mesothelioma Updates, Episode 5: Future Approaches
Mesothelioma Updates, Episode 5: Future Approaches
Mesothelioma Updates, Episode 4: Chemo and Immunotherapy
Mesothelioma Updates, Episode 4: Chemo and Immunotherapy
Mesothelioma Updates, Episode 3: Surgical Options
Mesothelioma Updates, Episode 3: Surgical Options
Mesothelioma Updates, Episode 2: Diagnosis and Staging
Mesothelioma Updates, Episode 2: Diagnosis and Staging
Mesothelioma Updates, Episode 1: Epidemiology
Mesothelioma Updates, Episode 1: Epidemiology
Targeted Therapies Forum, Episode 9: Telemedicine and Cancer
Targeted Therapies Forum, Episode 9: Telemedicine and Cancer
Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy
Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy
Targeted Therapies Forum, Episode 6: Coverage, Cost, and Standard of Care for Biopsy
Targeted Therapies Forum, Episode 6: Coverage, Cost, and Standard of Care for Biopsy
Targeted Therapies Forum, Episode 5: Circulating Tumor DNA
Targeted Therapies Forum, Episode 5: Circulating Tumor DNA
Melanoma Updates -- Leptomeningeal Disease/ Brain Mets in Melanoma
Melanoma Updates -- Leptomeningeal Disease/ Brain Mets in Melanoma
Melanoma Updates - Adjuvant Treatment Options for Melanoma
Melanoma Updates - Adjuvant Treatment Options for Melanoma
Melanoma Updates - Molecular Profiling and Driver Mutations in Melanoma Treatment
Melanoma Updates - Molecular Profiling and Driver Mutations in Melanoma Treatment
Melanoma Updates - The Importance of Screening for Skin Cancers
Melanoma Updates - The Importance of Screening for Skin Cancers
Melanoma Updates The Role of Neoadjuvant Treatment in Melanoma Care
Melanoma Updates The Role of Neoadjuvant Treatment in Melanoma Care
Melanoma Updates  Treatment Options for Metastatic Melanoma
Melanoma Updates Treatment Options for Metastatic Melanoma
Melanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma
Melanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Sto caricando